KFM and Omnicell announce strategic collaboration intended to strengthen healthcare inventory management
July 2026 – KFM, a leading provider of healthcare support services owned by King’s College Hospital NHS Foundation Trust, is pleased to announce a new strategic collaboration with Omnicell designed to deliver a comprehensive, future-ready inventory management solution for healthcare organisations.
From L-R: Guillaume Collin, Commercial Marketing Director (Omnicell), John Halter, Director of Product Marketing (Omnicell), Ed Platt, Senior Commercial Director (Omnicell), Nish Parekh Chief Strategy Officer (Omnicell), Preeya Bailie, Managing Director (KFM), Jaymin Shah, Director of Supply Chain (KFM) and Jason Woosley, SVP, Chief Product Officer (Omnicell).
The solution pairs Omnicell’s smart automation and intelligent inventory management software with KFM’s end-to-end operational service, and is intended to support improved patient safety, stronger financial sustainability, and enhanced supply chain efficiency across NHS and wider healthcare settings.
As part of the launch, KFM and Omnicell have released a new video illustrating many of the real challenges clinicians often face, such as stockouts, waste, and manual processes, and the expected transformational benefits of a digitally enabled, operationally governed model.
Speaking about the arrangement, Preeya Bailie, KFM Managing Director said: “We believe better inventory management has a direct impact on patient care, operational efficiency and overall system resilience.
By combining Omnicell’s interconnected smart automation with KFM’s end-to-end managed service, we aim to unlock meaningful efficiencies, reduce waste and help ensure clinicians have the right products at the right time.
This collaboration offers a seamless solution that is built to be future-ready and support the NHS’s ongoing transformation, and we are proud to be working with Omnicell to deliver this level of innovation and reliability.”
As part of this offering, Omnicell will provide the digital backbone of the solution, through smart automation and intelligent software that is designed to deliver real-time stock visibility, automated replenishment, accurate product data and seamless interoperability with EPR, P2P and IMU systems. Engineered to be compliant with Scan4Safety and GS1 Standards, the solution is intended to enhance traceability and patient safety, with planned ongoing upgrades to match evolving healthcare needs.
Alongside this, KFM will deliver the full operational service, including catalogue management, procure-to-pay receiving, distribution and clinical stockroom support. The service will be underpinned by robust governance, structured reporting and disciplined supply chain processes, meant to ensure organisations can optimise usage, minimise waste and gain full visibility and control across their supply chain.
Ed Platt, Senior Commercial Director, Omnicell, said: "In our view, getting healthcare supply chains right has never mattered more. Omnicell's automation, analytics, and connected workflows, combined with KFM's operational expertise, is intended to give organisations the real-time visibility and traceability to make better-informed supply chain decisions, faster."
The combined solution was created to directly support clinicians by helping to ensure supplies are available where and when they are needed, meant to reduce time spent managing stock and free up capacity for patient care. It also is intended to support long-term financial sustainability by improving data quality, reducing waste and avoiding unnecessary expenditure.
Roy Clarke, Chief Financial Officer at King’s College Hospital NHS Foundation Trust and KFM Board Member, said: “This collaboration represents an exciting step forward for KFM and the organisations we support, uniting the strengths of two organisations committed to improving outcomes for the NHS.
By pairing digital intelligence with a managed service, we are focused on reducing waste, making better use of resources, enhancing operational resilience and supporting safe, high-quality care while protecting financial sustainability.”
KFM remains committed to advancing innovation and excellence in healthcare, reinvesting all cost savings and benefits into the NHS to enhance services and deliver meaningful improvements to patient care. The collaboration with Omnicell strengthens this commitment and positions both organisations to support healthcare providers now and into the future.
The video is available to watch here: https://youtu.be/9YANPhbg8CY
-
Media Enquiries
For media enquiries, please contact:
KFM Marketing & Communications Louise Davies, Head of Marketing & Communications
kch-tr.kfmcommunications@nhs.netOmnicell Marketing Kerry Barnard, Senior Marketing Manager, UK & Ireland
marketinguk@omnicell.com -
KFM provides healthcare support services, partnering with healthcare organisations enabling them to deliver world class patient care. KFM is owned by King’s College Hospital NHS Foundation Trust making KFM a public authority. With a turnover of around £220 million, all KFM’s cost savings and benefits are reinvested in the NHS. KFM’s end-to-end managed services cover all areas and specialties including procuring and supplying all clinical supplies, medical equipment plus maintenance, training and technical support and outpatient pharmacy dispensing services.
Recognised for their innovative and collaborative approach, KFM has won multiple awards highlighting its dedication to delivering first class healthcare support services. In March 2023, KFM received the 'Procurement Project of the Year' award for the second time and was highly commended for 'Most Effective Contribution to Patient Safety' at the HSJ Partnership Awards. Additionally, KFM was awarded the 'Best Consultancy Partnership with the NHS' award at the HSJ Partnership Awards 2021 as well as winning the 'Best Use of Technology in Acute Care' at the Building Better Healthcare Awards 2021.
With over 350 staff, KFM are committed to supporting their workforce and local community, which was highlighted in 2023 when KFM received a Gold Award from the Ministry of Defence Employer Recognition Scheme for its positive role in supporting the Armed Forces community.
-
Since 1992, Omnicell has been committed to delivering innovative, outcomes-centric solutions for medication and supplies management across all settings of care. As an intelligent healthcare technology company, Omnicell empowers autonomous medication and supplies management by unifying automation and AI-enabled intelligence, optimized by expert services, to drive clinical and business outcomes that are helping to improve efficiency and enhance patient safety for healthcare facilities worldwide. Learn more at omnicell.com.
OMNICELL and the Omnicell logo are registered trademarks of Omnicell, Inc. or one of its subsidiaries.
Forward-Looking Statements
To the extent any statements contained in this press release deal with information that is not historical, these statements are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995.
Without limiting the foregoing, statements including the words “expect,” “intend,” “may,” “will,” “should,” “would,” “could,” “plan,” “potential,” “anticipate,” “believe,” “forecast,” “guidance,” “outlook,” “goals,” “target,” “estimate,” “seek,” “predict,” “project,” and similar expressions are intended to identify forward-looking statements. Forward-looking statements are subject to the occurrence of many events outside Omnicell’s control.
Such statements include, but are not limited to, Omnicell’s expectations regarding the collaboration with KFM and the related objectives and expected benefits (and any implied financial impact). Actual results and other events may differ significantly from those contemplated by forward-looking statements due to numerous factors that involve substantial known and unknown risks and uncertainties. These risks and uncertainties include, among other things, (i) unfavorable general economic and market conditions, including the impact and duration of inflationary pressures, (ii) Omnicell’s ability to take advantage of growth opportunities and develop and commercialize new solutions and enhance existing solutions, (iii) risks related to Omnicell’s investments in new business strategies or initiatives, (iv) risks related to the incorporation of artificial intelligence technologies, including generative or agentic AI technologies, into our products, services and processes or our vendors offerings and (v) other risks and uncertainties further described in the “Risk Factors” section of Omnicell’s most recent Annual Report on Form 10-K, as well as in Omnicell’s other reports filed with or furnished to the United States Securities and Exchange Commission (“SEC”), available at www.sec.gov.
Forward-looking statements should be considered in light of these risks and uncertainties. Investors and others are cautioned not to place undue reliance on forward-looking statements. All forward-looking statements contained in this press release speak only as of the date of this press release. Omnicell assumes no obligation to update any such statements publicly, or to update the reasons actual results could differ materially from those expressed or implied in any forward-looking statements, whether as a result of changed circumstances, new information, future events, or otherwise, except as required by law.